Daniel Y Wang

5PUBLICATIONS
46CO-AUTHORS
Medical devicesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Apr 10, 2025
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.

Hee-Jin Jang, Meera Patel, Daniel Y Wang

|Mar 29, 2023
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.

Daniel Wang, Caroline E Porter, Bora Lim

|Dec 05, 2022
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.

Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni

|Mar 13, 2020
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

Daniel Y Wang, Jennifer L McQuade, Rajat R Rai

Pageof 1

Frequent Collaborators

2 joint publications

Bryan M Burt

2 joint publications

Jong Min Choi

2 joint publications

Meera Patel

2 joint publications

Maheshwari Ramineni